<i>JAK2</i> is a critical therapeutic target in <scp>VEXAS</scp> syndrome treated with ruxolitinib
Andrea Ceccardi(Ospedale Policlinico San Martino), Gabriele Zoppoli(Ospedale Policlinico San Martino), Andrea Bellodi(Ospedale Policlinico San Martino), Mario Stabile(Institut Jules Bordet), Isabella Lombardo(Bridge Pharma (United States)), Monica Colombo(Ospedale Policlinico San Martino), Anna Garuti(Ospedale Policlinico San Martino), Tiziana Vigo(Ospedale Policlinico San Martino), Davide Ceresa(Ospedale Policlinico San Martino), Martina Dameri(Ospedale Policlinico San Martino), Matteo Dragani(Ospedale Policlinico San Martino), Giulia Rivoli(Ospedale Policlinico San Martino), Alberto Ballestrero(Ospedale Policlinico San Martino), Francesco Ravera(Ospedale Policlinico San Martino), Lorenzo Ferrando(Ospedale Policlinico San Martino), Irene Solimano(University of Genoa), Benedetta Cigolini(Ospedale Policlinico San Martino)
Cited by 8
Related Papers
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
|The Lancet Oncology|2021|355
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
|Journal of Clinical Oncology|2023|109